| Name | Title | Contact Details |
|---|---|---|
Luciana Mansolelli |
Chief Quality Officer | Profile |
Ilya Koltover |
Chief Transformation Officer | Profile |
There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA approved treatment. Glycomine develops therapeutics for diseases which have no treatment options.
Marsh is a global leader in insurance broking and risk management. Marsh helps clients succeed by defining, designing, and delivering innovative industry-specific solutions that help them effectively manage risk. Marsh’s approximately 26,000 colleagues work together to serve clients in more than 130 countries. Marsh is a wholly owned subsidiary of Marsh & McLennan Companies (NYSE:MMC), a global professional services firm offering clients advice and solutions in the areas of risk, strategy, and human capital. With 55,000 employees worldwide and annual revenue exceeding $12 billion, Marsh & McLennan Companies is also the parent company of Guy Carpenter, a global leader in providing risk and reinsurance intermediary services; Mercer, a global leader in talent, health, retirement, and investment consulting; and Oliver Wyman, a global leader in management consulting.
Vitro Naturals is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kira Biotech is an emerging Australian biotechnology company developing novel immunomodulatory compounds for the treatment of immune system disorders.
Genizon BioSciences Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.